| GU Malignancies - Prostate |
|
|
|
|
|
In October 2006, a multidisciplinary approach to treating high risk GU Malignancies was the focus of a symposium in Monte Carlo, Monaco. It brought together an expert faculty panel of Urologists, Medical Oncologists and Radiation Oncologists for an in-depth discussion on the new opportunities and controversies in treatment. The advent of new pharmaceutical treatments, refined surgical procedures and combination therapies potentially redefine the standard of care and increase survival with quality of life. UroToday.com is pleased to offer the following 11 new state-of-the-art presentations focusing on the latest approaches to high risk and advanced prostate cancer. You can also view the 5 new presentations for high risk and advanced renal cell carcinoma. Prostate Cancer Ongoing Trials and the Future In Hormone Refractory Prostate Cancer The Role Of Bisphosphonates In Metastatic Prostate Cancer The Increasing Responsibility Of The Urologist In Maintaining Bone Health In Prostate Cancer Patients Chemotherapy For High-Risk Disease At RRP Prevention Of Prostate Cancer:Is This The Way To Go? Identifying The High Risk Patient:What Is Available? The Role Of Surgery In The High Risk Patient The Role Of Bisphosphonates In The High Risk Patient The Role Of Radiation Therapy In The High Risk Patient Treating PSA Recurrence Hormone-Refractory Prostate Cancer
Please log-in or register in order to submit comments. Powered by AkoComment! |
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2008 UroToday ® All Rights Reserved |






GU Malignancies 
